Following the close of its new €1bn fund, ArchiMed chair and founding partner Denis Ribon talks to Alessia Argentieri about the fundraising and investment strategy of the firm’s latest vehicle, as well as portfolio management and its deal pipeline amid the coronavirus crisis
